Kiat Ruxrungtham, M.D.

Scientific Mentor & Founder

As Scientific Mentor & Founder of Chula VRC, Kiat Ruxrungtham conducts vaccine research work and gathering professors and researchers interested in the research and development of vaccines into Center of Excellence in Vaccine Research and Development. He spent more than 30 years exploring HIV treatment strategies, HIV T cell immunology, vaccine development (including dengue, HIV and house dust mite (HDM) vaccine); and strategies to improve DNA vaccine immunogenicity. He has supervised and lead Chula VRC’s effect to rapidly advance the promising HDM vaccine candidates from the lab bench to clinical trial.

Ruxrungtham holds a Professor of Medicine from Department of Medicine, Chulalongkorn University. He is providing teaching and patient care at the King Chulalongkorn Memorial Hospital, and is mentoring junior researchers on vaccine, immunology research and also on clinical trials. He currently is a vice president for research and innovation, Chulalongkorn University.

He has published more than 230 peer review papers on HIV, immunology and allergy. He is a faculty member of the faculty 1000 of Medicine, a chief editor of Asia Pacific J of Allergy and editorial board member of Immunology, ImmunoTargets and Therapy, Asian Biomedicine, and the Scientific Report. He is also a reviewer for > 9 journals.

Kanitha Patarakul , M.D. , Ph.D.

Director of Chula VRC and Principal Investigator of Leptospirosis Research Group

As the Director of Chula VRC, Kanitha Patarakul is a co-founder and fully support all of activities in Chula VRC. She provides expertise in pathogenesis of Leptospirosis, development of Leptospirosis vaccine and led the team of Leptospirosis Research Group as PI.

She and her team currently focusing on Pathogenesis of leptospirosis: identification and function determination of outer membrane proteins as potential vaccine candidates, the development of leptospirosis vaccine and testing in animal models: DNA and Subunit (recombinant protein) vaccine using different types of adjuvants.

She holds Assistant Professor from Division of Bacteriology, Department of Microbiology, Faculty of Medicine, Chulalongkorn University. Patarakul qualified in Doctor of Medicine at Faculty of Medicine Chulalongkorn University in Bangkok, Thailand, has a PhD from Georgetown University, Washington DC, USA and completed a visiting professor at Monash University, Melbourne, Australia.

Alain Jacquet, Ph.D.

Co-Director Chula VRC and Principal Investigator of Laboratory of Molecular Allergology

Alain Jacquet join Chula VRC with extensive experience in the production and purification of recombinant DNA or proteins and, specifically, in the design of new immunotherapeutics and diagnosis assays.

Jacquet is Associate Professor on Chulalongkorn University Faculty of Medicine and has PhD from the Universite Libre de Bruxelles (ULB, Belgium). He previously worked at the Laboratory of Experimental Allergology (ULB) for 20 years where he served as a group leader. Long focusing on House dust mite, he brings to Chula VRC a deep knowledge of the House dust mite allergen and vaccine.

Sunee Sirivichayakul, Ph.D.

Principal Investigator of Vaccine and Cellular Immunology Laboratory

Sunee Sirivichayakul holds a Ph.D. in Immunology and Microbiology from Chulalongkorn University, where she was also graduated with a bachelor and master degree. She pursued a research fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, U.S.A.
Sirivichayakul has had almost 30 years experience in HIV virology and immunology.
The HIV molecular biology that she mastered from Harvard Medical School enabled her to develop Thailand's first in-house HIV drug resistance testing which has been used for service and research for more than 20 years. She is a founding member of Chula VRC where she leads the HIV DNA vaccine research.

Chutitorn Ketloy, Ph.D.

Principal Investigator of Dengue Vaccine Research Unit

Chutitorn Ketloy received her Ph.D. from Chulalongkorn University (Biomedical Sciences). Currently, she is the assistant professor at Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University. For her research, she has been a research investigator at Chula Vaccine Research Center, Chula VRC since 2008. She served as a principal investigator and project coordinator in DNA-based dengue vaccine which has been evaluated in mice and non-human primates.

Supranee Buranapraditkun, Ph.D.

Senior Leadership

Buranapraditkun’s current research focuses on an acute HIV infection cohort (RV254) to study earliest immune response in the periphery and lymph node. She is interested in T and B cells involved in immune responses to acute HIV-1 infection in order to better understand the mechanisms of the responses and to enhance vaccine design and development.

Buranapraditkun completed a postdoctoral fellow at the U.S. Military HIV Research Program (MHRP) with Dr. Hendrik Streeck’s laboratory in 2014-2015. She focused on how T follicular helper cells communicate with B cells and how their interaction drives the development of broadly neutralizing antibodies that may be protective when induced prophylactically. In 2016, she moved a postdoctoral fellow to Dr. Lydie Trautmann’s laboratory. She focused on immune cell dynamics in lymph node and blood during acute HIV infection.

She graduated with a PhD in Molecular Biology and Immunology from the Interdisciplinary Medical Microbiology Graduate School at Chulalongkorn University in 2012. She was a coordinator of the NIH contract #NO1-A1-30024 at the Thailand site focusing on “HLA Typing and Epitope Mapping Relative to Vaccine Design” (2004-2008) with Professor Todd M. Allen. She has been involved in the previous phase I: DNA/rfawlpox vaccine trial related to intracellular cytokine staining assays. Here, she is a medical technologist at Chulalongkorn University’s Vaccine and Cellular Immunology Laboratory since 1995. During her research, she worked with Professor Kiat Ruxrungtham in the Division of Allergy and Clinical Immunology.

Eakachai Prompetchara, Ph.D.

Senior Leadership

Eakachai Prompetchara received his Ph.D. in Biomedical Sciences from Chulalongkorn University in 2014. He has a comprehensive knowledge in Immunology, Virology and Molecular Biology. He has been working on dengue DNA vaccine since he was a Ph.D. student and continuing such research during his postdoctoral fellowship under a supervision of Professor Kiat Ruxrungtham.

Prompetchara is currently a lecturer at Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University. His current research focuses on the development of viral vaccine by using various platforms including nucleic acid-based vaccine (DNA, mRNA), virus-like particles and recombinant proteins.

He also works on the establishment of humanized mice model for vaccine immunogenicity testing and pathogenesis in collaboration with Professor Bradford K. Berges, Brigham Young University, UT, USA.

Siwaporn Boonyasuppayakorn, M.D., Ph.D.

Senior Leadership

Siwaporn Boonyasuppayakorn is a Virology lecturer of Department of Microbiology, Faculty of Medicine, Chulalongkorn University. After M.D. graduation in 2007, she began her research career with molecular and demographic analysis of respiratory syncytial virus infection under supervision of Associate Professor Parvapan Bhattarakosol, Ph.D. Her contribution included characterizing the novel lineage of genotype B in Thailand for the first time.

In 2009-2013, she continued her Ph.D. study with anti-dengue drug discovery and functional analysis of flaviviral enzymes under supervision of Professor Radhakrishnan Padmanabhan, Ph.D. in Georgetown University Medical Center, Washington, DC, USA. Her contributions included characterizing amodiaquine antimalarials as a dengue virus inhibitor and functional analysis of NS5 N- terminal domain for enzymatic activities. After graduation, she resumed her faculty position in Chulalongkorn University and continued working with anti-flaviviral drug discovery.
She started her independent research focusing on academic drug discovery. She and her team modified the classic plaque assay and equipped with automated quantification system using economical approach for medium-scale drug screening. Currently, she is characterizing drug candidates originated and modified from natural products for anti-dengue and Zika viruses using rational drug design.   


Patrawadee Pitakpolrat


Tewarit Soongrung


Sirikarn Jitthamstaporn


Pratomporn Krangvichian


Pattarawat Tantiworasit


Kittipan Tharakhet


Suwanna Mekprasan


Teerasit Techawiwattanaboon